CN112584834A - 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物 - Google Patents

用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物 Download PDF

Info

Publication number
CN112584834A
CN112584834A CN201980050370.7A CN201980050370A CN112584834A CN 112584834 A CN112584834 A CN 112584834A CN 201980050370 A CN201980050370 A CN 201980050370A CN 112584834 A CN112584834 A CN 112584834A
Authority
CN
China
Prior art keywords
acid
compound
extranodal
cell lymphoma
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980050370.7A
Other languages
English (en)
Other versions
CN112584834B (zh
Inventor
陶荣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN112584834A publication Critical patent/CN112584834A/zh
Application granted granted Critical
Publication of CN112584834B publication Critical patent/CN112584834B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

提供一种用于治疗结外NK/T细胞淋巴瘤的喹啉衍生物。所提供的化合物I或其药学上可接受的盐,可用于治疗门冬酰胺耐药的结外NK/T细胞淋巴瘤患者,尤其对于门冬酰胺耐药的、复发或难治性结外NK/T细胞淋巴瘤患者,疗效评估结果表明其症状得到缓解,其生存期得到延长。
Figure DDA0002920766330000011

Description

PCT国内申请,说明书已公开。

Claims (10)

  1. PCT国内申请,权利要求书已公开。
CN201980050370.7A 2018-08-06 2019-08-05 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物 Active CN112584834B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810886395 2018-08-06
CN2018108863958 2018-08-06
PCT/CN2019/099264 WO2020029918A1 (zh) 2018-08-06 2019-08-05 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物

Publications (2)

Publication Number Publication Date
CN112584834A true CN112584834A (zh) 2021-03-30
CN112584834B CN112584834B (zh) 2022-04-12

Family

ID=69413410

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980050370.7A Active CN112584834B (zh) 2018-08-06 2019-08-05 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物

Country Status (2)

Country Link
CN (1) CN112584834B (zh)
WO (1) WO2020029918A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113750096A (zh) * 2020-06-02 2021-12-07 正大天晴药业集团股份有限公司 用于治疗外周t细胞淋巴瘤的喹啉衍生物
JP7546757B2 (ja) 2020-08-07 2024-09-06 石薬集団中奇制薬技術(石家庄)有限公司 ミトキサントロン塩酸塩リポソームとペグアスパラガーゼの使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102216332A (zh) * 2008-10-31 2011-10-12 艾伯特生物治疗学公司 抗-cs1抗体用于治疗罕见淋巴瘤的用途
CN103483319A (zh) * 2007-03-14 2014-01-01 南京爱德程医药科技有限公司 作为血管生成抑制剂的螺取代化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103483319A (zh) * 2007-03-14 2014-01-01 南京爱德程医药科技有限公司 作为血管生成抑制剂的螺取代化合物
CN102216332A (zh) * 2008-10-31 2011-10-12 艾伯特生物治疗学公司 抗-cs1抗体用于治疗罕见淋巴瘤的用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HUANG, YL ET AL.: "Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type", 《BLOOD》 *
金震等: "自分泌PDGF/PDGFR环路对NK/T细胞淋巴瘤细胞增殖的影响及其机制研究", 《白血病 淋巴瘤》 *
黄小银: "NK/T细胞淋巴瘤发病机制研究进展", 《中国肿瘤临床》 *

Also Published As

Publication number Publication date
CN112584834B (zh) 2022-04-12
WO2020029918A1 (zh) 2020-02-13

Similar Documents

Publication Publication Date Title
CN107001326B (zh) 抗非小细胞肺癌的喹啉衍生物
CN115624550B (zh) 一种用于治疗胃癌的喹啉衍生物
CN113710658A (zh) 用于治疗尤因肉瘤的喹啉类化合物或其药学上可接受的盐
JP2024533423A (ja) 薬学的組成物およびその使用
CN112584834B (zh) 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物
CN115025090A (zh) 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒
CN118678958A (zh) 药物组合物及其用途
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
US20130101680A1 (en) Radiotherapy enhancer
WO2020057536A1 (zh) 用于治疗脑肿瘤的喹啉衍生物
CN111757736B (zh) 治疗鼻咽癌的喹啉衍生物
CN111757737B (zh) 用于治疗三阴性乳腺癌的喹啉衍生物
CN106999485B (zh) 抗肺鳞癌的喹啉衍生物
CN112533600B (zh) 用于治疗小细胞肺癌的喹啉衍生物
RU2827402C2 (ru) Фармацевтическая композиция, содержащая пиридинаминное соединение, и ее применение при ros1-положительном немелкоклеточном раке легкого
CN112105361A (zh) 用于治疗非小细胞肺癌的喹啉衍生物
CN111110681A (zh) 喹啉衍生物联合卡培他滨在治疗肝癌的用途
CN115463143A (zh) 非天然人参皂苷3β,12β-Di-O-Glc-PPD治疗脑瘤的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant